Plexxicon | GenomeWeb

Plexxicon

This week, Certara said that Plexxikon has selected its D360 software solution to support data access and analysis for its drug discovery projects.

Since BRAF inhibitors such as Roche/Plexxicon's vemurafenib, or PLX 4032, are currently in clinical trials for melanoma patients, the authors think there could be a rapid transition of their findings to the clinic.

By exploring a treatment strategy that involves Roche/Plexxikon's investigational pharmacogenomically targeted drug vemurafenib and Bristol-Myers Squibb's newly approved melanoma treatment Yervoy, two large drug developers are hoping to further improve outcomes for a genomically defined patient population.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.